Xencor, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
XNCR Nasdaq 2836 www.xencor.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Xencor, Inc.

Bi/Multispecific Drugs in Oncology Analytical Tool Featuring Top Developers - Amgen, Hoffmann-La Roche, J&J, Xencor, Biocytogen - Unlocking New Precision, Immune Activation, and Therapeutic Potential - May 12th, 2026 3:22 am
These Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under Threat - May 8th, 2026 5:11 am
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates - May 6th, 2026 3:10 pm
Xencor Reports First Quarter 2026 Financial Results - May 6th, 2026 2:01 pm
Xencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026 - May 6th, 2026 4:12 am
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW - May 4th, 2026 6:01 am
Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates - Apr 30th, 2026 6:45 pm
Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst calls - Mar 24th, 2026 7:36 am
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast - Mar 4th, 2026 2:01 pm
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates - Feb 25th, 2026 6:05 pm
Xencor: Q4 Earnings Snapshot - Feb 25th, 2026 2:19 pm
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results - Feb 25th, 2026 2:01 pm
Xencor to Participate at Upcoming Investor Conferences - Feb 23rd, 2026 2:01 pm
What Catalysts Are Rewriting The Xencor (XNCR) Story In A Recovering Biopharma Sector - Feb 8th, 2026 4:11 pm
Xencor (XNCR): BofA Bullish on US Biopharmaceuticals Coverage - Jan 29th, 2026 10:24 pm
Could Early XmAb819 Signals Reshape Xencor’s (XNCR) Broader T‑Cell Engager Investment Narrative? - Jan 20th, 2026 5:07 am
Xencor (XNCR) Valuation Check After New Oncology And Autoimmune Pipeline Milestones - Jan 18th, 2026 7:10 pm
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - Jan 14th, 2026 1:30 am
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones - Jan 8th, 2026 6:01 am
Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR) - Dec 31st, 2025 3:46 am